No1(2) 2019
Back to the issue
|
DOI 10.37219/2528-8253-2019-1-49 |
Bereznyuk VV, Chernokur AA, Gaponenko YaYu
Investigation of the effectiveness of the drug «Glenspray active» in
patients with allergic rhinitis
|
Bereznyuk Vladimir V.
Dnipropetrovsk Medical Academy, Head of the Department of Otolaryngology,
Doctor of Medical Sciences, Pro-fessor.
Email: otologg@gmail.com
Chernokur Alexander A.
Dnipropetrovsk Medical Academy, associate professor of the Department of
Otolaryngology, candidate of medi-cal sciences.
E-mail: onkolog@rambler.ru
Orchid: https://orcid.org/0000-0003-1908-3929 |
|
Abstract
Relevance: Over the past decade, an increase in the number of
patients with AR has been noted. According to epidemiological studies
conducted in different countries, the prevalence of AR is from 1 to 40%. In
most European countries, 10-25% of the population suffers from allergic
rhinitis. Of particular interest for treatment are combination preparations
containing topical corticosteroids and antihistamines, in particular,
Glenspray Active.
The active ingredients of the drug are mometasone furoate and azelastine
hydrochloride.
The purpose: study of effectiveness of the drug «Glenspray Active»
usage in patients with allergic rhinitis.
Results and discussion: 69 patients with allergic rhinitis were
treated in the clinic of the SE «DMA of HM of Ukraine». In 61 patients
intermittent AR was diagnosed, in 8 patients - persistent AR. Efficiency
criteria were an assessment of the effect of therapy with the studied drug
on the nasal symptoms of allergic rhinitis. To analyze the indicators, a
general nasal symptom scale (TNSS – Total Nasal Symptom Score) was used, and
the overall effectiveness of treatment by the patient and the research
doctor was also evaluated. Most of patients (49-57%) noted a good and
excellent effect from the use of the drug which occurred already between 30
and 60 minutes after the start of treatment. 85.5% of patients noted the
maximum effect of the using of the drug which was between 30 and 60 minutes.
Conclusion: The combined drug «Glenspray Active» is an effective and
safe tool in the treatment of patients with AR. A good and excellent
clinical effect in the form of a significant reduction in nasal symptoms
(TNSS) occurs from 30 to 60 minutes in 44-57% of patients. The maximum
effect from the use of the drug was observed between 30 and 60 minutes in
85.5% of patients. |
|
Keywords
allergic rhinitis, Glenspray Active |
|
Reference
- Pukhlik BM, Pukhlik SM, Koritskaya IV, Gonko VN, Kovpak AB, et al.
[Current views on the treatment of allergic rhinitis]. Ukrainian
Pulmonology Journal. 2004;(2):18-21. [Article in Russian]
- Allergic rhinitis and its impact on asthma (ARIA) 2008 Update (in
collaboration with World Health Organization, GA2LEN and AllerGen).
Allergy; 2008 (Suppl. 86):8-160.
- Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its
impact on asthma. J Allergy Clin Immunol.
2001 Nov;108(5 Suppl):S147-334.
doi: 10.1067/mai.2001.118891.
- Schafer T, Ring J. Epidemiology of allergic diseases. Allergy.
1997;52(38 Suppl):14-22.
doi:10.1111/j.1398-9995.1997.tb04864.x.
|
|
